An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

Avidity Biosciences, Inc. (RNA) is an early stage biopharma with a multi-billion dollar valuation. These types of companies always interest me. On the one hand, due to their early stages, they appear ...

ALLISON GATLIN Wed, November 13, 2024 at 9:07 PM UTC 2 min read Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on RNA stock, giving a Buy rating on November 28. Joseph Schwartz has given his Buy rating due to a combination of factors ...

In a deal that could bring Avidity Biosciences Inc. $2.3 billion if all milestones are met, Bristol Myers Squibb Co. gained global rights to Avidity’s antibody oligonucleotide conjugates platform to ...

While data on functional endpoints are still to come, Avidity Biosciences Inc. executives said the firm is moving ahead with plans for a BLA filing by the end of 2025 for del-zota, an ...